Reduced excretion of a melatonin metabolite in workers exposed to 60 Hz magnetic fields

American Journal of Epidemiology

Volumn 150, Issue 1, 1999, Pages 27-36

  Burch, James B ^a   Reif, John S ^a   Yost, Michael G ^b   Keefe, Thomas J ^a   Pitrat, Charles A ^a  

^a Department of Environmental and Radiological Health Sciences   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

6 hydroxymelatonin sulfate; Electricity; Electromagnetic fields; Pineal body

Indexed keywords

CREATININE; MELATONIN;

ADULT; ARTICLE; HUMAN; LIGHT EXPOSURE; MAGNETIC FIELD; METABOLITE; OCCUPATIONAL EXPOSURE; RADIOIMMUNOASSAY; URINALYSIS;

EID: 0033168216     PISSN: 00029262     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.aje.a009914     Document Type: Article

References (67)

1. Savitz DA. Overview of epidemiological research on electric and magnetic fields and cancer. Am Ind Hyg Assoc J 1993;54:197-204.
2. Kheiffets LI, Abdelmonem AA, Buffler PA, et al. Occupational electric and magnetic field exposure and brain cancer: a metaanalysis. J Occup Environ Med 1995;37:1327-41.
3. Reiter RJ. Melatonin suppression by static and extremely low frequency electromagnetic fields: relationship to the reported increased incidence of cancer. Rev Environ Health 1994;10: 171-86.
4. Stevens RG, Davis S. The melatonin hypothesis: electric power and breast cancer. Environ Health Perspect 1996;104:135-40.
5. Reiter RJ. Alterations of the circadian melatonin rhythm by the electromagnetic spectrum: a study in environmental toxicology. Regul Toxicol Pharmacol 1992;15:226-44.
6. Burch JB, Reif JS, Yost MG, et al. Nocturnal excretion of a urinary melatonin metabolite in electric utility workers. Scand J Work Environ Health 1998;24:183-9.
7. Pfluger DH, Minder CE. Effects of exposure to 16.7 Hz magnetic fields on urinary 6-hydroxymelatonin sulfate excretion of Swiss railway workers. J Pineal Res 1996;21:91-100.
8. Reuss S, Olcese J. Magnetic field effects on rat pineal gland: role of retinal activation by light. Neurosci Lett 1986;64:97-101.
9. Olcese J, Reuss S, Vollrath L. Evidence for the involvement of the visual system in mediating magnetic field effects on pineal melatonin synthesis in the rat. Brain Res 1985;333:382-4.
10. Phillips JB, Deutschlander ME. Magnetoreception in terrestrial vertebrates: implications for possible mechanisms of EMF interaction with biological systems. In: Stevens R, Wilson BW, Anderson LE, eds. The melatonin hypothesis. Columbus, OH: Batelle Press, 1997:111-72.
11. Cagnacci A. Melatonin in relation to physiology in adult humans. J Pineal Res 1996;21:200-13.
12. Brzezinski A. Melatonin in humans. N Engl J Med 1997;336:186-95.
13. Blask DE. Melatonin in oncology. In: Yu H, Reiter RJ, eds. Melatonin biosynthesis, physiological effects, and clinical applications. Boca Raton, FL: CRC Press, 1993:447-75.
14. Panzer A, Viljoen M. The validity of melatonin as an oncostatic agent. J Pineal Res 1997;22:184-202.
15. Conti A, Maestroni GJM. The clinical neuroimmunotherapeutic role of melatonin in oncology. J Pineal Res 1995;19:103-10.
16. Nelson RJ, Demas GE, Klein SL, et al. The influence of season, photoperiod, and pineal melatonin on immune function. J Pineal Res 1995;19:149-65.
17. Reiter RJ, Melchiorri D, Sewerynek E, et al. A review of the evidence supporting melatonin's role as an antioxidant. J Pineal Res 1995;18:1-11.
18. Tan DX, Reiter RJ, Chen LD, et al. Both physiological and pharmacological levels of melatonin reduce DNA adduct formation induced by the carcinogen safrole. Carcinogenesis 1994;15:215-18.
19. Manev H, Tolga U, Kharlamov A, et al. Increased brain damage after stroke or excitotoxic seizures in melatonin-deficient rats. FASEB J 1996;10:1546-51.
20. Cohen M, Lippman M, Chabner B. Role of the pineal gland in the aetiology and treatment of breast cancer. Lancet 1978;2:814-16.
21. Voordouw BCG, Euser R, Verdonk RER, et al. Melatonin and melatonin-progestin combinations alter pituitary-ovarian function in women and can inhibit ovulation. J Clin Endocrinol Metab 1992;74:108-17.
22. Stevens RG. Electric power use and breast cancer: a hypothesis. Am J Epidemiol 1987;125:556-61.
23. Demers PA, Thomas DB, Rosenblatt KA, et al. Occupational exposure to electromagnetic fields and breast cancer in men. Am J Epidemiol 1991;134:340-7.
24. Matanoski GM, Breysse PN, Elliott EA. Electromagnetic field exposure and breast cancer. (Letter). Lancet 1991;337:737.
25. Tynes T, Anderson A. Electromagnetic fields and male breast cancer. (Letter). Lancet 1990;2:1596.
26. Floderus B, Tornqvist S, Stenlund C. Incidence of selected cancers in Swedish railway workers. Cancer Causes Control 1994;5:189-94.
27. Loomis DP, Savitz DA. Breast cancer mortality among female electrical workers in the United States. J Nat Cancer Inst 1994;86:921-5.
28. Coogan PF, Clapp RW, Newcomb PA, et al. Occupational exposure to 60-hertz magnetic fields and risk of breast cancer in women. Epidemiology 1996;7:459-64.
29. Tynes T, Hannevik M, Andersen A, et al. Incidence of breast cancer in Norwegian female radio and telegraph operators. Cancer Causes Control 1996;7:197-204.
30. Guenel P, Raskmark P, Andersen JB, et al. Incidence of cancer in persons with occupational exposure to electromagnetic fields in Denmark. Br J Ind Med 1993;50:758-84.
31. Thériault G, Goldberg M, Miller AB, et al. Cancer risks associated with occupational exposure to magnetic fields among electric utility workers in Ontario and Quebec, Canada, and France: 1970-1989. Am J Epidemiol 1994;139:550-72.
32. Rosenbaum PF, Vena JE, Zielezny MA, et al. Occupational exposures associated with male breast cancer. Am J Epidemiol 1994;139:30-6.
33. Stenlund C, Floderus B. Occupational exposure to magnetic fields in relation to male breast cancer and testicular cancer: a Swedish case-control study. Cancer Causes Control 1997;8:184-91.
34. Deadman JE, Camus M, Armstrong BG, et al. Occupational and residential 60-Hz electromagnetic fields and high frequency electric transients: exposure assessment using a dosimeter. Am Ind Hyg Assoc J 1988;49:409-19.
35. Bracken TD. Exposure assessment for power frequency electric and magnetic fields. Am Ind Hyg Assoc J 1993;54:197-204.
36. Sahl JD, Kelsh MA, Smith RW, et al. Exposure to 60 Hz magnetic fields in the electric utility work environment. Bioelectromagnetics 1994;15:21-32.
37. Bowman JD, Garabrant DH, Sobel E, et al. Exposures to extremely low frequency electromagnetic fields in occupations with elevated leukemia rates. Appl Ind Hyg 1988;3:189-94.
38. Villeneuve PJ, Agnew DA, Corey PN, et al. Alternate indices of electric and magnetic field exposures among Ontario electrical utility workers. Bioelectromagnetics 1998;19:140-51.
39. Litovitz TA, Penafiel M, Krause D, et al. The role of temporal sensing in bioelectromagnetic effects. Bioelectromagnetics 1997;18:388-95.
40. Litovitz TA, Krause D, Mullins JM. Effect of coherence of the applied magnetic field on ornithine decarboxylase activity. Biochem Biophys Res Commun 1991;178:862-5.
41. Litovitz TA, Krause D, Montrose CJ, et al. Temporally incoherent magnetic fields mitigate the response of biological systems to temporally coherent magnetic fields. Bioelectromagnetics 1994;15:399-409.
42. Thomas DC, Peters JM, Bowman JD, et al. Temporal variability in residential magnetic fields and risk of childhood leukemia. Palo Alto, CA: Electric Power Research Institute, 1995. (Exposure to residential electric and magnetic fields and risk of childhood leukemia) (EPRI report no. TR-104528).
43. Arendt J, Bojkowski C, Franey C, et al. Immunoassay of 6-hydroxymelatonin sulfate in human plasma and urine: abolition of the urinary 24-hour rhythm with atenolol. J Clin Endocrinol Metab 1985;60:1166-73.
44. Aldous ME, Arendt J. Radioimmunoassay for 6-sulphatoxymelatonin in urine using an iodinated tracer. Ann Clin Biochem 1988;25:298-303.
45. Bojkowski CJ, Arendt JA, Shih MC, et al. Melatonin secretion in humans assessed by measuring its metabolite, 6-sulfatoxymelatonin. Clin Chem 1987;33:1343-8.
46. Wilson BW, Wright CW, Morris JE, et al. Evidence for an effect of ELF electromagnetic fields on human pineal gland function. J Pineal Res 1990;9:259-69.
47. Coon SL, Mazuruk K, Bernarn M, et al. The human serotonin N-acetyltransferase (EC 2.3.1.87) gene (AANAT): structure, chromosomal localization, and tissue expression. Genomics 1996;34:76-84.
48. Waldhauser F, Weizenbacher G, Tatzer E, et al. Alterations in nocturnal serum melatonin levels in humans with growth and aging. J Clin Endocrinol Metab 1988;66:648-52.
49. Sack RL, Lewy AJ, Erb DL, et al. Human melatonin production decreases with age. J Pineal Res 1986;3:379-88.
50. Arendt J, Hampton S, English J, et al. 24-Hour profiles of melatonin, cortisol, insulin, C-peptide, and GIP following a meal and subsequent fasting. Clin Endocrinol (Oxford) 1982;16:89-95.
51. Claustrat B, Chazot G, Brun J, et al. A chronobiological study of melatonin and cortisol secretion in depressed subjects: plasma melatonin, a biochemical marker in major depression. Biol Psychiatry 1984;19:1215-28.
52. Iguchi H, Kato KI, Ibayashi H. Melatonin serum levels and metabolic clearance rate in patients with liver cirrhosis. J Clin Endocrinol Metab 1982;54:1025-7.
53. Mallo C, Zaidan R, Galy G, et al. Pharmacokinetics of melatonin in man after intravenous infusion and bolus injection. Eur J Clin Pharmacol 1990;38:297-301.
54. Beck-Friis J, von Rosen D, Kjellman BF, et al. Melatonin in relation to body measures, sex, age, season and the use of drugs in patients with major affective disorders and healthy subjects. Psychoneuroendocrinology 1984;9:261-77.
55. Kennaway DJ, Royles P. Circadian rhythms of 6-sulfatoxymelatonin, cortisol, and electrolyte excretion at the summer and winter solstices in normal men and women. Acta Endocrinologica (Copenhagen) 1986;113:450-6.
56. Levine ME, Milliron AN, Duffy LK. Diurnal and seasonal rhythms of melatonin, cortisol, and testosterone in interior Alaska. Arctic Med Res 1994;53:25-34.
57. Bojkowski CJ, Arendt J. Annual changes in 6-sulfatoxymelatonin excretion in man. Acta Endocrinologica (Copenhagen) 1988;117:470-6.
58. Martikainen H, Tapanainen J, Vakkuri O, et al. Circannual concentrations of melatonin, gonadotropins, prolactin and gonadal steroids in males in a geographic area with large annual variation in daylight. Acta Endocrinologica 1985;109: 446-50.
59. Dubocovich ML. Melatonin receptor: are there multiple subtypes? Trends Pharmacol Sci 1995;16:50-6.
60. Baldwin WS, Barrett JC. Melatonin: receptor-mediated events that may affect breast and other steroid hormone-dependent cancers. Mol Carcinog 1998;21:149-55.
61. Wood AW, Armstrong SM, Sait ML, et al. Changes in human plasma melatonin profiles in response to 50 Hz magnetic field exposure. J Pineal Res 1998;116-27.
62. Laakso M-L, Porkka-Heiskanen T, Alila A, et al. Twenty-four-hour rhythms in relation to the natural photoperiod: a field study in humans. J Biol Rhythms 1994;9:283-93.
63. Wehr TA, Moul DE, Barbato G, et al. Conservation of photoperiod-responsive mechanisms in humans. Am J Physiol 1993;265(4, part 2):R846-R857.
64. Kennaway DJ, Earl CR, Shaw PF, et al. Phase delay of the rhythm of 6-sulphatoxymelatonin excretion by artificial light. J Pineal Res 1987;4:315-20.
65. Wiltschko W, Wiltschko R. Magnetic orientation in animals. Zoophysiology. Vol 33. Berlin: Springer-Verlag, 1995:222-33.
66. Mahnke FH. Color, environment, and human response. New York: Van Rostrand Reinhold, 1996.
67. Zelanski P, Fischer MP. Color. Englewood Cliffs, NJ: Prentice Hall, 1989.